...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: Supporting developing country production capacity through technology transfer
【24h】

WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: Supporting developing country production capacity through technology transfer

机译：世卫组织在大流行时增加全球和公平获得流感疫苗的举措：通过技术转让支持发展中国家的生产能力

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Should a highly pathogenic avian influenza virus, such as the H5N1 virus type currently circulating in birds, become transmissible among humans, an effective vaccine, rapidly available in vast quantities, would be the best tool to prevent high case-fatalities and the breakdown of health and social services. The number of vaccine doses that could be produced on demand has risen sharply over the last few years; however, it is still alarmingly short of the 13 billion doses that would be needed if two doses were required to protect fully the world's population. Most developing countries would be last in the queue to benefit from a pandemic vaccine. The World Health Organization, together with governments, the pharmaceutical industry and other stakeholders, has been implementing the global pandemic influenza action plan to increase vaccine supply since 2006. Building capacity in developing countries to manufacture influenza vaccine is an integral part of this plan, as well as research and development into more efficacious technologies, e.g. those that allow significant dose-sparing. To this end, the influenza vaccine technology transfer initiative was launched in 2007 and, to date, vaccine manufacturers in 11 developing countries have received grants to acquire the capacity to produce inactivated or live attenuated influenza vaccine for their populations. In addition, a centralized 'hub' has been established to facilitate training in the new technologies for scientists and regulators in the countries. This supplement of Vaccine is devoted to showcasing the interim results of the WHO initiative and the impressive progress made by the developing country manufacturers
机译：如果高致病性禽流感病毒（例如当前在鸟类中传播的H5N1型病毒）在人类中可以传播，那么一种有效的，可大量大量获得的疫苗将是预防高致病性和破坏健康的最佳工具。和社会服务。在过去的几年中，可以按需生产的疫苗剂量数量急剧增加。但是，如果仍需要两剂来充分保护世界人口，它仍然远远不足以达到需要的130亿剂。大多数发展中国家将排在最后，以从大流行疫苗中受益。自2006年以来，世界卫生组织一直与各国政府，制药业和其他利益相关者一道实施全球大流行性流感行动计划，以增加疫苗供应。在发展中国家，制造流感疫苗的能力建设是该计划的组成部分，因为以及研发更有效的技术，例如那些可以节省大量剂量的药物。为此，2007年启动了流感疫苗技术转让计划，迄今为止，已有11个发展中国家的疫苗生产商获得了赠款，以为其人群生产灭活或减毒活流感疫苗的能力。此外，还建立了一个集中的“枢纽”，以促进对各国科学家和监管机构进行新技术培训。这份疫苗补充资料专门展示了WHO倡议的中期结果以及发展中国家制造商取得的令人瞩目的进展

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号